REAL SCIENCE. REAL POSSIBILITIES.Produced naturally by the body, LL-37 forms part of our defences and is being explored for antimicrobial activity, inflammation and wound healing.
LL-37 has direct biological relevance because it is part of human innate defence. Its actions can be antimicrobial, inflammatory or repair-related depending on concentration and context.
These cards show what LL-37 is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
Topical wound repair is the clearest clinical-development area.
A first-in-man trial reported faster healing at 0.5 and 1.6 mg/mL. The larger phase IIb trial was neutral overall, with an exploratory signal in larger ulcers.
LL-37 can act against a range of microbes in laboratory systems.
Laboratory antimicrobial activity does not establish that systemic dosing treats human infection.
LL-37 influences keratinocytes, endothelial cells and repair signalling.
Preclinical work supports re-epithelialisation and wound-environment effects.
LL-37 can recruit and modify immune-cell responses.
The same context-dependent biology may support defence or contribute to inflammatory disease.
LL-37 has credible wound and host-defence biology. The useful question is how a concentration-dependent topical signal translates—not whether every route inherits the same benefit.
Endogenous antimicrobial and immune signalling
→Keratinocyte, vascular and wound responses
→Early positive signal, larger mixed result
→Injected use has no comparable human programme
LL-37 combines antimicrobial action, immune signalling and tissue repair. Two venous-leg-ulcer trials bring that biology into people, while their mixed results and non-linear dose response argue against broad route-independent claims.
LL-37 is an endogenous cathelicidin with direct antimicrobial and immune-modulating functions.
Keratinocyte migration, angiogenesis and wound-environment effects connect host defence with tissue closure.
A small first-in-man study was encouraging; a 148-person phase IIb study was neutral overall.
Neither trial establishes injected immune support, infection treatment or a general healing dose.
34 people with hard-to-heal venous leg ulcers
148 people with hard-to-heal venous leg ulcers
Small randomized topical wound trials provide direct human evidence.
Clinical efficacy is not established across wound types, infections or systemic use.
Topical trial safety data exist, but systemic and long-term safety are uncertain.
A large mechanistic literature covers antimicrobial, immune and repair effects.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Two topical venous-ulcer trials; phase IIb neutral overall
Extensive antimicrobial, barrier and immune biology
No validated systemic dose, efficacy or long-term safety
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
Wound repair, biofilm questions and host defence—mapped against genuine topical human trials and the much larger gap around systemic use.
Community goals · topical trial data · route boundaryInterest centres on chronic infections, immune resilience and wound repair. The most credible positive human signal is topical wound research, not systemic self-treatment.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
The published topical trial is often cited as proof of broad healing potential.
Small randomized venous-ulcer studies provide a genuine early clinical signal.
Keratinocyte migration, angiogenesis and antimicrobial research support the wound rationale.
Promising for a specific topical setting, not proof for all wounds or routes.
People discuss LL-37 for persistent infections and biofilms.
No general systemic infection indication or validated injectable protocol is established.
Direct antimicrobial and immune-modulating activity is well documented in laboratory systems.
Strong biology; clinical treatment claims remain unproven.
Its endogenous host-defence role is often simplified into an immune-boosting claim.
Endogenous function does not show that more LL-37 improves outcomes.
Effects can be protective or pro-inflammatory depending on tissue and concentration.
Context matters; 'more' is not necessarily better.
Topical, nasal and injected descriptions are often discussed as if they were interchangeable.
The direct human evidence is limited to formulated topical wound treatment with compression care.
Exposure, tissue concentration and inflammatory effects change with route and formulation.
A topical trial cannot validate systemic self-administration.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toLL-37, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
The example below reflects recurring community discussion about injected LL-37. The human studies used formulated topical cream on ulcers with compression care.
Anecdotal systemic starting amount
Optional community-described step-up
Short course descriptions vary
No evidence-based break interval
The wound trials used 0.5–3.2 mg/mL cream applied twice weekly within structured wound care. Concentration in a topical formulation does not equal systemic exposure.
The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
Published human LL-37 protocols are topical wound-study protocols, not evidence for injected or general immune-support dosing.
34 people with hard-to-heal venous leg ulcers
Published study structure, shown as data — not a personal dosing schedule.
The two lower concentrations showed the strongest signal; the highest did not outperform placebo. This cannot be converted into an injection regimen.
148 people with hard-to-heal venous leg ulcers
Published study structure, shown as data — not a personal dosing schedule.
No significant benefit in the full cohort. The larger-ulcer result was post hoc and needs confirmation.
Community injection descriptions often start around 100 mcg/day and may move toward 200 mcg/day. These amounts have no validating human dose-finding study.
Short 2–4-week courses are commonly described; topical use is product- and wound-specific.
No validated systemic titration, maintenance or break schedule exists.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Topical LL-37 + Compression / wound care
LL-37 + Thymosin alpha-1
LL-37 + BPC-157
The strongest human setting is topical venous-ulcer care; systemic antimicrobial and immune-support use remains unvalidated.
Compression and wound care belong to the tested clinical context. Thymosin alpha-1 is a community rationale, not a proven synergy.
Human trials evaluated LL-37 as an adjunct within structured wound care.
Relevant only to the studied topical wound setting.Community pairing combines host-defence and immune-modulation narratives.
No controlled combination trial establishes added benefit or safety.Often framed as combining antimicrobial or barrier defence with repair signalling.
There is no controlled human evidence for this pairing, route or combined safety.Topical wound evidence cannot be transferred to an injected immune stack.
Suspected infection needs diagnosis and appropriate antimicrobial care, not an experimental pairing.
Combining immune-active compounds can increase uncertainty rather than create balanced immunity.
Two randomized venous-ulcer trials provide condition-specific tolerability data beyond laboratory research alone.
LL-37 can be antimicrobial, repair-supporting, inflammatory or cytotoxic depending on concentration and tissue context.
Injected pharmacokinetics, organ exposure, interaction risk and long-term immune effects are not established in people.
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Hard-to-heal ulcers and suspected infection can require vascular review, debridement, compression or antimicrobial treatment.
Milligrams per millilitre in a cream does not describe absorbed dose or validate a systemic amount.
Unapproved injectable products add contamination, concentration and sequence-verification uncertainty.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
LL-37 is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.
